BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
10.06
-0.28 (-2.71%)
At close: May 13, 2025, 4:00 PM
10.14
+0.08 (0.80%)
Pre-market: May 14, 2025, 7:00 AM EDT

BioCryst Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
May '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
2,1051,5581,2272,1402,4921,315
Upgrade
Market Cap Growth
49.65%26.97%-42.68%-14.12%89.45%147.49%
Upgrade
Enterprise Value
2,6392,0701,6752,4352,6031,253
Upgrade
Last Close Price
10.067.525.9911.4813.857.45
Upgrade
PS Ratio
4.143.463.707.9015.8673.85
Upgrade
PB Ratio
-4.66-3.27-2.69-7.26-23.29-68.29
Upgrade
EV/Sales Ratio
5.244.595.058.9916.5670.34
Upgrade
EV/EBITDA Ratio
70.431194.32----
Upgrade
Debt / Equity Ratio
-1.83-1.77-1.86-2.52-5.54-14.51
Upgrade
Debt / EBITDA Ratio
20.87208.58----
Upgrade
Asset Turnover
1.060.900.620.480.340.07
Upgrade
Inventory Turnover
9.8210.117.7112.0018.93-
Upgrade
Quick Ratio
2.782.492.974.505.182.93
Upgrade
Current Ratio
2.932.633.314.895.463.07
Upgrade
Return on Equity (ROE)
------1925.37%
Upgrade
Return on Assets (ROA)
4.54%-0.16%-11.57%-16.30%-24.07%-41.60%
Upgrade
Return on Capital (ROIC)
5.71%-0.21%-14.70%-19.88%-29.76%-55.37%
Upgrade
Earnings Yield
-2.54%-5.71%-18.47%-11.55%-7.39%-13.90%
Upgrade
FCF Yield
-1.28%-3.41%-7.93%-7.63%-5.80%-10.31%
Upgrade
Buyback Yield / Dilution
-5.50%-7.54%-3.38%-3.79%-7.08%-44.70%
Upgrade
Updated May 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q